CNS Treatment Developer Supernus Pharma (SUPN) Lowers IPO Expectations
Tweet Send to a Friend
Down)
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) filed an amended registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The Company lowered its expected offering, now expecting to sell 11 million common shares are a price of $5 per share.
Supernus previously expected to sling 5,769,000 shares at an expected price range of $12 to $14 per share.
The pharma plans to list on the Nasdaq Global Market under the ticker "SUPN."
The offering is being made through Citigroup, Piper Jaffray, Cowen and Company, and Stifel Nicolaus Weisel.
Supernus is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Supernus previously expected to sling 5,769,000 shares at an expected price range of $12 to $14 per share.
The pharma plans to list on the Nasdaq Global Market under the ticker "SUPN."
The offering is being made through Citigroup, Piper Jaffray, Cowen and Company, and Stifel Nicolaus Weisel.
Supernus is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Supernus to Present at Two Investor Conferences
- Evoke Pharma (EVOK) Files $24M IPO
- Tableau Software (DATA) IPO now indicated $42-$44
Create E-mail Alert Related Categories
IPOsRelated Entities
Piper Jaffray, Stifel Nicolaus, Citi, Cowen & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
